This is a firm commitment public offering of shares of Class A common stock (“common stock”) of BioVie Inc. Prior to this offering, there has been a limited public market for our common stock on the OTCQB Marketplace under the ticker BIVI. We are selling up to 1,311,189 shares of common stock. There are no selling shareholders in this offering.
On August 5, 2019, the last reported sale price for our common stock as reported on the OTCQB Marketplace was $11.44 per share, after giving effect to our planned 1:125 reverse stock split. The final public offering price will be determined through negotiation between us and the lead underwriters in the offering and the recent market price used throughout this prospectus may not be indicative of the final offering price. Our common stock has been approved for listing on The NASDAQ Capital Market under the symbol “BIVI”.
Investing in our common stock is highly speculative and involves a high degree of risk. See “Risk Factors” beginning on page 5.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
Per Share Total Initial public offering price $ $ Underwriting discounts and commissions (1) $ $ Proceeds to us, before expenses $ $
(1) Underwriting discounts and commissions do not include a non-accountable expense allowance equal to 1.0% of the public offering price payable to the underwriters. We refer you to the “Underwriting” section of this prospectus beginning on page 53 for additional information regarding the underwriters’ compensation.
We have granted a 45-day option to the representative of the underwriters to purchase up to 196,678 additional shares of common stock solely to cover over-allotments, if any.
The underwriters expect to deliver the shares to purchasers on or about , 2019.